overcoming resistance to chemotherapy, Nat Rev Cancer, 2003;3(7):502–16.
7. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al., Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum- sensitive ovarian cancer in late relapse, J Clin Oncol, 2010;28(20):3323–9.
8. Parmar MK LJ, Ledermann JA, Colombo N, et al., Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, Lancet, 2003;361(9375):2099–106.
9. Pfisterer J, Plante M, Vergote I, et al., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J Clin Oncol, 2006;24(29):4699–707.
10. Ozols RF, Treatment goals in ovarian cancer, Int J Gynecol Cancer, 2005;15(Suppl. 1):3–11.
11. Monk BJ, Herzog TJ, Kaye SB, et al., Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer, J Clin Oncol, 2010;28(19):3107–3114.
12. Carswell EA, Old LJ, Kassel RL, et al., An endotoxin-induced serum factor that causes necrosis of tumors, Proc Natl Acad Sci U S A, 1975;72(9):3666–70.
13. Blick M, Sherwin SA, Rosenblum M, Gutterman J, Phase I study of recombinant tumor necrosis factor in cancer patients, Cancer Res, 1987;47(11):2986–9.
14. Haranaka K, Satomi N, Sakurai A, Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice, Int J Cancer, 1984;34(2):263–7.
15. Schiller JH, Storer BE, Witt PL, et al., Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly, Cancer Res, 1991;51(6):1651–8.
16. Pfizenmaier K, Scheurich P, Schluter C, Kronke M, Tumor necrosis factor enhances HLAA, B,C and HLA-DR gene expression in human tumor cells, J Immunol, 1987;138(3):975–80.
17. Collins T, Lapierre LA, Fiers W, et al., Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro, Proc Natl Acad Sci U S A, 1986;83(2):446–50.
18. Scheurich P, Thoma B, Ucer U, Pfizenmaier K, Immunoregulatory activity of recombinant human tumor
necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNFalpha-mediated enhancement of T cell responses, J Immunol, 1987;138(6):1786–90.
19. Feinman R, Henriksen-DeStefano D, Tsujimoto M, Vilcek J, Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes, J Immunol, 1987:635–40.
20. Ziegler-Heitbrock HW, Moller A, Linke RP, et al., Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity, Cancer Res, 1986;46(11):5947–52.
21. Decker T, Lohmann-Matthes ML, Gifford GE, Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages, J Immunol, 1987;138(3):957–62.
22. Talmadge JE, Tribble HR, Pennington RW, et al., Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice, Cancer Res, 1987;47(10):2563–70.
23. Curnis F, Sacchi A, Borgna L, et al., Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13), Nat Biotechnol, 2000;18(11):1185–90.
24. Asher A, Mule JJ, Reichert CM, et al., Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo, J Immunol, 1987;138(3):963–74.
25. Schiller JH, Witt PL, Storer B, et al., Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor, Cancer, 1992;69(2):562–71.
26. Creagan ET, Kovach JS, Moertel CG, et al., A phase I clinical trial of recombinant human tumor necrosis factor, Cancer, 1988;62(12):2467–71.
27. Eggermont AM, Schraffordt Koops H, Lienard D, et al., Isolated limb perfusion with highdose tumor necrosis factor- alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial, J Clin Oncol, 1996;14(10):2653–65.
28. Lienard D, Ewalenko P, Delmotte JJ, et al., High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J Clin Oncol, 1992;10(1):52–60.
29. Fraker DL, Alexander HR, Andrich M, Rosenberg SA, Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study, J Clin Oncol, 1996;14(2):479–89.
30. Alexander HR Jr., Bartlett DL, Libutti SK, et al., Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver, J Clin Oncol, 1998;16(4):1479–89.
31. Rath U, Kaufmann M, Schmid H, et al., Effect of intraperitoneal recombinant human tumor necrosis factor alpha on malignant ascites, Eur J Cancer, 1991;27(2):121–5.
32. Curnis F, Sacchi A, Corti A, Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration, J Clin Invest, 2002;110(4):475–82.
33. Arap W, Pasqualini R, Ruoslahti E, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, Science, 1998;279(5349):377–80.
34. Ellerby HM, Arap W, Ellerby LM, et al., Anti-cancer activity of targeted pro-apoptotic peptides, Nat Med, 1999;5(9):1032–8.
35. Du Bois A, Luck HJ, Pfisterer J, et al., [Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum], Zentralbl Gynakol, 2000;122(5):255–67.
36. Cairns R, Papandreou I, Denko N, Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment, Mol Cancer Res, 2006;4(2):61–70.
37. Sacchi A, Gasparri A, Gallo-Stampino C, et al., Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha, Clin Cancer Res 2006;12(1):175-82.
38. S.r.l. NMS. NGR-hTNF: effect on the toxicity of doxorubicin after three-cycle intravenous treatments (one combined treatment every three weeks) in the cynomolgus monkey, MolMed SpA, internal data, 2005.
39. Gregorc V, Santoro A, Bennicelli E, et al., Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours, Br J Cancer, 2009;101(2):219–24.
40. Scambia G, Lorusso D, Amadio G, et al., Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer (OC), J Clin Oncol, 2011;29(Suppl.): abstract 5022 (proceedings of the American Society of Clinical Oncology annual meeting, 3–7 June 2011, Chicago, US).
41. Van Heeckeren WJ, Bhakta S, Ortiz J, et al., Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?, J Clin Oncol, 2006;24(10):1485–8.
42. Ten Hagen TL, Van der Veen AH, Nooijen PT et al., Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma- bearing rats, Int J Cancer, 2000;87(6):829–37.
EUROPEAN OBSTETRICS & GYNAECOLOGY
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60